Please login to the form below

Not currently logged in

KRAS mutation

This page shows the latest KRAS mutation news and features for those working in and with pharma, biotech and healthcare.

Amgen aims for first KRAS inhibitor approval in the US

Amgen aims for first KRAS inhibitor approval in the US

In NSCLC, KRAS G12C is the most common KRAS mutation, with around 13% of patients with NSCLC in the US carrying this particular mutation. ... Data from the phase 1 trial found that seven (53%) of 13 experienced NSCLC patients with the KRAS G12C mutation

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....